Compare AMTX & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMTX | CING |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.6M | 93.1M |
| IPO Year | 2023 | N/A |
| Metric | AMTX | CING |
|---|---|---|
| Price | $2.40 | $5.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $12.00 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 2.4M | 660.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,194,000.00 | N/A |
| Revenue This Year | $68.03 | N/A |
| Revenue Next Year | $50.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 174.60 | N/A |
| 52 Week Low | $1.22 | $3.20 |
| 52 Week High | $3.66 | $11.89 |
| Indicator | AMTX | CING |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 43.69 |
| Support Level | $2.17 | $3.62 |
| Resistance Level | $2.40 | $6.85 |
| Average True Range (ATR) | 0.34 | 0.64 |
| MACD | -0.09 | -0.16 |
| Stochastic Oscillator | 0.01 | 16.10 |
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.